slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 29,191-29,220
Pages 10,126
Rows per page 30
Component
29,191-29,220 of 303,780
06
The chart highlights the significant outperformance of Pershing Square (696.2%) compared to the S&P 500 (132.1%).Pershing Square Portfolio (multi-position annual update) · Pershing Square Capital Management
Activist deck Activist investor Beat · Interest2 hits
39
The slide uses callout boxes to link specific corporate milestones to share price movements.Pershing Square Portfolio (multi-position annual update) · Pershing Square Capital Management
Activist deck Activist investor Beat · Action2 hits
44
The chart tracks share price from Jan 2014 to Dec 2014, ending at $224.Pershing Square Portfolio (multi-position annual update) · Pershing Square Capital Management
Activist deck Activist investor Beat · ActionLoop · Before After2 hits
69
The slide highlights a negative performance outcome for the activist investor's position.Pershing Square Portfolio (multi-position annual update) · Pershing Square Capital Management
Activist deck Activist investor Beat · Action2 hits
48
The slide uses callout boxes to annotate specific dates on a line chart.Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · The Breakthrough2 hits
49
The slide uses a line chart with callout boxes to link specific negative events to stock price drops.Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · The Breakthrough2 hits
65
Pershing Square Portfolio (multiple positions)Pershing Square Portfolio (multiple positions) · Pershing Square
Activist deck Activist investor Beat · Ultimate Achievement2 hits
13
Multiple holdings (Pershing Square portfolio)Multiple holdings (Pershing Square portfolio) · Pershing Square
Activist deck Activist investor 2 hits
53
The slide highlights EBITDA decline, FX headwinds, leadership turnover, guidance cuts, and high leverage.Multiple holdings (Pershing Square portfolio) · Pershing Square
Activist deck Activist investor Loop · Cost Of Inaction2 hits
61
The chart highlights the decline from the $10.50 entry point to the $8.28 price as of April 2016.Multiple holdings (Pershing Square portfolio) · Pershing Square
Activist deck Activist investor 2 hits
110
The slide includes a summary table of undiscounted cash flows and a detailed table of discounted cash flows at a 10% discount rate.Allergan, Inc. (AGN) · William Ackman
Activist deck Activist investor 2 hits
01
Fannie Mae & Freddie Mac (FNMA / FMCC)Fannie Mae & Freddie Mac (FNMA / FMCC) · William Ackman
Conference presentation Activist investor Beat · Situation & Context2 hits
16
The U.S. column is highlighted with a dashed oval to emphasize its outlier status regarding MBS funding.Fannie Mae & Freddie Mac (FNMA / FMCC) · William Ackman
Conference presentation Activist investor Beat · Problem & Complication2 hits
17
Fannie Mae & Freddie Mac (FNMA / FMCC)Fannie Mae & Freddie Mac (FNMA / FMCC) · William Ackman
Conference presentation Activist investor Beat · Solution & Approach2 hits
57
Fannie Mae & Freddie Mac (FNMA / FMCC)Fannie Mae & Freddie Mac (FNMA / FMCC) · William Ackman
Conference presentation Activist investor Beat · Impact & Next StepsLoop · Cost Of Inaction2 hits
69
The slide uses a historical narrative to support the thesis that private capital in this sector is inherently pro-cyclical and unreliable.Fannie Mae & Freddie Mac (FNMA / FMCC) · William Ackman
Conference presentation Activist investor Beat · Impact & Next StepsLoop · Cost Of Inaction2 hits
74
Fannie Mae & Freddie Mac (FNMA / FMCC)Fannie Mae & Freddie Mac (FNMA / FMCC) · William Ackman
Conference presentation Activist investor Beat · Impact & Next StepsLoop · Cost Of Inaction2 hits
93
Fannie Mae & Freddie Mac (FNMA / FMCC)Fannie Mae & Freddie Mac (FNMA / FMCC) · William Ackman
Conference presentation Activist investor Beat · Impact & Next StepsLoop · Cost Of Inaction2 hits
01
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · Pershing Square Holdings
Press release Activist investor 2 hits
10
The slide uses a simple list format to explain the value proposition of specialty pharmacies followed by a logo grid of industry participants.Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Evidence2 hits
20
The table serves as a precedent for regulatory risk and financial impact in the pharmaceutical industry.Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Preempt Rebuttal2 hits
21
The slide uses a 'villain' framing by contrasting the high penalties of established peers against the absence of the target company (Valeant).Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Preempt Rebuttal2 hits
31
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Activist deck Activist investor Beat · Resolution2 hits
06
The chart uses callout boxes to correlate specific acquisition announcements with share price movements.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 2 hits
11
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain2 hits
19
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor Loop · Logic Chain2 hits
42
The chart uses a box-plot style to show ranges for different comparable categories.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 2 hits
46
The slide details specific financial ratios (90% conversion, 4x leverage target, 5.75% cost of debt) and compares them to current/transaction-specific metrics.Valeant Pharmaceuticals International (VRX) · William Ackman
Conference presentation Activist investor 2 hits
17
This is a page from a formal letter/report, likely legal or regulatory in nature, focusing on corporate compliance and deceptive practices.Herbalife, Ltd. (HLF) · David Klafter
Shareholder letter Activist investor Beat · Impact & Next Steps2 hits
01
Valeant Pharmaceuticals International (VRX)Valeant Pharmaceuticals International (VRX) · Pershing Square Holdings
Press release Activist investor Beat · Attention2 hits